Pharma News

In a historic leap for global health, an international team of scientists has developed the world’s first genetically engineered, product-ready snake antivenom — a potential game-changer for treating bites from some of Africa’s most lethal snakes, including cobras, mambas, and rinkhals.

The U.S. Food and Drug Administration (FDA) has announced new measures aimed at accelerating the development of biosimilar medicines and lowering the overall cost of biologic treatments in the United States.

Pharmaceutical major Cipla Limited has announced the signing of definitive agreements to acquire 100% equity stake in Inzpera Healthsciences Limited, a company engaged in developing and marketing differentiated paediatric and wellness products. The announcement was made through a corporate filing with the Bombay Stock Exchange

Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received tentative approval from the United States Food and Drug Administration (USFDA) for Budesonide delayed-release capsules, 4 mg (USRLD: Tarpeyo Capsules, 4 mg).

Pfizer Inc. announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A. in the Delaware Court of Chancery. The lawsuit includes claims for breach of contract, breach of fiduciary duty, and tortious interference in contract arising from Metseras alleged breach of its obligations under the merger agreement between Pfizer and Metsera.

Semaglutide significantly reduced major adverse cardiovascular events in patients with overweight or obesity with cardiovascular disease but without diabetes, as per recent research study conducted by University College London.

The U.S. Food and Drug Administration today announced actions to restrict the sale of unapproved ingestible fluoride prescription drug products for children. The FDA sent notices to four companies outlining the agencys intention to take enforcement action against those marketing unapproved fluoride-containing ingestible drugs labeled for use in children under age 3 or older children at low or moderate risk for tooth decay.

A multiple sclerosis patient in the UK was the first to receive CAR T cell therapy, invented by UCL researchers, in a clinical trial testing whether this personalised treatment can slow or even halt the progression of the disease.